The Biodistribution and Radiation Dosimetry of the Arg-Gly-Asp Peptide 18F-AH111585 in Healthy Volunteers

Article Figures & Data

Download figure
Open in new tab
Download powerpoint
FIGURE 1.
Series of whole-torso images of representative subject showing biodistribution of ¹⁸F activity for acquisitions begun between 5 and 208 min after administration of ¹⁸F-AH111585. p.i. = after administration.

TABLE 1

Cumulated Activities Normalized to Administered Activity for ¹⁸F-AH111585

		Administered activity (MBq·h/MBq)
Organ/tissue	n^*	Mean	SD
Gallbladder contents	3	0.006	0.001
Gastrointestinal tract^†
Wall	8	0.218	0.148
Small intestine contents	6	0.211	0.056
Upper large intestine contents	6	0.116	0.031
Lower large intestine contents	6	0.021	0.005
Voided feces	6	0.001	0.001
Heart
Wall	8	0.077	0.020
Contents	8	0.043	0.006
Kidneys	8	0.155	0.031
Liver	8	0.234	0.048
Lungs	8	0.140	0.017
Salivary glands	2	0.005	0.002
Spleen	8	0.048	0.014
Thyroid gland	2	0.005	0.004
Urinary bladder contents and voided urine^‡	8	0.456	0.146
Remainder	8	1.065	0.110

↵* Number of subjects in which organ or tissue was visualized.
↵† Calculated using ICRP Publication 30 (14) model.
↵‡ Calculated for 3.5-h voiding interval using dynamic urinary bladder model in Stabin et al. (15).

TABLE 2

Organ- and Tissue-Absorbed Doses Normalized to Administered Activity for ¹⁸F-AH111585

	Administered activity (μGy/MBq)
Organ/tissue	Mean	SD
Adrenals	15	1
Brain	6	1
Breasts	7	1
Gallbladder wall	21	4
Gastrointestinal tract
Lower large intestine wall	23	7
Small intestine wall	44	22
Stomach wall	12	1
Upper large intestine wall	49	26
Cardiac wall	59	10
Kidneys	102	19
Liver	35	6
Lungs	30	3
Muscle	9	1
Osteogenic cells	12	1
Ovaries	17	3
Pancreas	15	1
Red marrow	10	0.5
Skin	6	1
Spleen	57	15
Testes	9	1
Thymus	10	1
Thyroid	17	21
Urinary bladder wall	124	29
Uterus	19	3